Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
Clinical trial NCT02037074 · COMPLETED
Trial details
- NCT number
- NCT02037074
- Sponsor
- FORUM Pharmaceuticals Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-01
- Primary completion
- 2014-12-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.